How the Ozempic gold rush is causing 'deeply concerning' sho

The unprecedented demand for GLP-1 medicines, fuelled by their remarkable ability to help patients shed up to 20% of body weight, has been nothing short of explosive.

Related Keywords

United Kingdom , Denmark , Danish , Michael Kyle , Lars Fruergaard , Eli Lilly , Sarita Menon , Adrian Sanders , Diabetes Global Network , Novo Nordisk , United Kingdom Department Of Health , Parliamentary Diabetes Global Network , Pharmacist Network , Diabetes United , Bio Pharma , United Kingdom Department , Social Care , Markets Amp Regulations , Pipelines , Emerging Markets , Obesity , Diabetes ,